Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy

John W McEvoy, Seth S Martin, Zeina A Dardari, Michael D Miedema, Veit Sandfort, Joseph Yeboah, Matthew J Budoff, David C Goff Jr, Bruce M Psaty, Wendy S Post, Khurram Nasir, Roger S Blumenthal, Michael J Blaha
2017-01-10
Abstract:BackgroundThe use of atherosclerotic cardiovascular disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic of increasing interest. Therefore, we studied whether coronary artery calcium (CAC) can further guide the allocation of anti-hypertensive treatment intensity. MethodsWe included 3733 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with SBP between 120 and 179 mm Hg. Within subgroups categorized by both SBP (120–139 mm Hg, 140–159 mm Hg, and 160–179 mm Hg) and estimated 10-year ASCVD risk (using the American College of Cardiology/American Heart Assocation pooled-cohort equations), we compared multivariable-adjusted hazard ratios for the composite outcome of incident ASCVD or heart failure after further stratifying by CAC (0, 1–100, or >100). We estimated 10-year number-needed-to-treat for an intensive SBP goal of 120 …
What problem does this paper attempt to address?